We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
For patients with heart failure and reduced ejection fraction (HFrEF), sacubitril-valsartan does not impact aortic stiffness versus enalapril but is associated with improvements in cardiac structure and function...